StocksMedium•19 October 2026•
1 min read
FDA Approves Expansion of Alpha Tau’s Glioblastoma Clinical Trial
Key Facts
1The U.S. FDA approved an IDE supplement expanding the REGAIN trial for recurrent glioblastoma from 10 to 20 patients.
The U.S. FDA approved an IDE supplement to expand Alpha Tau Medical’s REGAIN clinical trial for recurrent glioblastoma. GlobeNewswire reported that the approval doubles the patient enrollment from 10 to 20 participants, enabling additional study endpoints and an interim analysis of the Alpha DaRT radiation therapy's effectiveness.
DRTS closed at $12.29 on October 16, 2026, after reaching a day high of $13.3 and a low of $11.99 during that session. The updated trial protocol also opens the study to patients with IDH-mutant grade 4 tumors and introduces regular quality-of-life assessments as part of the clinical evaluation.